Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pingye Zhang

Showing results (1-10 of 17) with videos related to

Pageof 2
Sort By:
Contemporary Clinical Trials|April 28, 2023
An extension to a 2-in-1 adaptive design with biomarker subpopulation selectionMan Jin, Pingye Zhang
Statistical Methods in Medical Research|February 16, 2021
An adaptive seamless Phase 2-3 design with multiple endpointsMan Jin, Pingye Zhang
Therapeutic Innovation & Regulatory Science|March 17, 2023
An Extended Framework of Multiple Testing in Group Sequential DesignMan Jin, Pingye Zhang
Contemporary Clinical Trials|July 5, 2025
2-in-1 adaptive design with dose optimization accounting for ranked dose responseMan Jin, Pingye Zhang
Journal of Biopharmaceutical Statistics|January 22, 2024
A win ratio-based framework to combine multiple clinical endpoints in exploratory basket trialsPingye Zhang, Xiaoyun Nicole Li
Contemporary Clinical Trials|September 29, 2022
A 2-in-1 adaptive design to seamlessly expand a selected dose from a phase 2 trial to a phase 3 trial for oncology drug developmentPingye Zhang, Xiaoyun Nicole Li, Kaifeng Lu, et al.
Journal of Biopharmaceutical Statistics|November 13, 2023
Covariate-adjusted value-guided subgroup identification via boostingJinchun Zhang, Pingye Zhang, Junshui Ma, et al.
Statistics in Medicine|August 14, 2020
A nonparametric method for value function guided subgroup identification via gradient tree boosting for censored survival dataPingye Zhang, Junshui Ma, Xinqun Chen, et al.
Genetic Epidemiology|July 23, 2013
Finding novel genes by testing G × E interactions in a genome-wide association studyW James Gauderman, Pingye Zhang, John L Morrison, et al.
Contemporary Clinical Trials|February 21, 2023
A variation of a 2-in-1 adaptive design to seamlessly expand a selected dose from a phase 2 trial to a phase 3 trial for oncology drug developmentPingye Zhang, Xiaoyun Nicole Li, Kaifeng Lu, et al.
Pageof 2

Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
Contemporary Clinical Trials|April 28, 2023
An extension to a 2-in-1 adaptive design with biomarker subpopulation selectionMan Jin, Pingye Zhang
Statistical Methods in Medical Research|February 16, 2021
An adaptive seamless Phase 2-3 design with multiple endpointsMan Jin, Pingye Zhang
Therapeutic Innovation & Regulatory Science|March 17, 2023
An Extended Framework of Multiple Testing in Group Sequential DesignMan Jin, Pingye Zhang
Contemporary Clinical Trials|July 5, 2025
2-in-1 adaptive design with dose optimization accounting for ranked dose responseMan Jin, Pingye Zhang
Journal of Biopharmaceutical Statistics|January 22, 2024
A win ratio-based framework to combine multiple clinical endpoints in exploratory basket trialsPingye Zhang, Xiaoyun Nicole Li
Contemporary Clinical Trials|September 29, 2022
A 2-in-1 adaptive design to seamlessly expand a selected dose from a phase 2 trial to a phase 3 trial for oncology drug developmentPingye Zhang, Xiaoyun Nicole Li, Kaifeng Lu, et al.
Journal of Biopharmaceutical Statistics|November 13, 2023
Covariate-adjusted value-guided subgroup identification via boostingJinchun Zhang, Pingye Zhang, Junshui Ma, et al.
Statistics in Medicine|August 14, 2020
A nonparametric method for value function guided subgroup identification via gradient tree boosting for censored survival dataPingye Zhang, Junshui Ma, Xinqun Chen, et al.
Genetic Epidemiology|July 23, 2013
Finding novel genes by testing G × E interactions in a genome-wide association studyW James Gauderman, Pingye Zhang, John L Morrison, et al.
Contemporary Clinical Trials|February 21, 2023
A variation of a 2-in-1 adaptive design to seamlessly expand a selected dose from a phase 2 trial to a phase 3 trial for oncology drug developmentPingye Zhang, Xiaoyun Nicole Li, Kaifeng Lu, et al.
Pageof 2